Juan Pablo Bagó, general director of pharma in Argentina for the Bagó group, discusses the state of R&D in Argentina, and explains why his group is planning for a 75 percent of turnover from international markets in the coming years.
2014 marked the 80th anniversary of Laboratorios Bagó, a market leader in Argentina and also Latin America, with products in in 47 countries. In this interview with Pharmaboardroom.com, Juan Pablo Bagó, general director of pharma in Argentina for the Bagó group, discusses the state of R&D in Argentina, and explains why his group is planning for a 75 percent of turnover from international markets in the coming years.
http://pharmaboardroom.com/interviews/bago-group-juan-pablo-bago-general-director-pharma-argentina/
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
Bristol Myers Squibb Reveals Promising Data for KarXT, a Potential Treatment for Schizophrenia
April 9th 2024A combination of data from the EMERGENT-4 trial and pooled data from the EMERGENT program showed the promise of KarXT (xanomeline-trospium) in providing symptom improvement for people with schizophrenia.